Characteristics and outcome of t(8;21) AML patients according to ASXL2 and ASXL1 mutational status
| Patient characteristics . | All patients (n = 110) . | ASXL1/2 wild-type (n = 74) . | ASXL1 mutant (n = 11) . | ASXL2 mutant (n = 25) . | P* . | P† . |
|---|---|---|---|---|---|---|
| Age, median [range] (years) | 31 [4-60] | 33 [4-59] | 35 [7-47] | 22 [4-60] | .265 | .227 |
| Sex (M/F) | 59/51 | 43/31 | 5/6 | 11/14 | .400 | .223 |
| WBC, median [range] (G/L) | 12.8 [1.3-163] | 10.7 [1.3-94.5] | 15.8 [3.4-48.2] | 20.3 [2.7-163] | .029 | .011 |
| Blasts, [range] % | 55 [17-98] | 58 [17-98] | 45 [28-81] | 50 [25-94] | .140 | .047 |
| Additional cytogenetic abnormalities | ||||||
| Loss of Y | 36/109 (33%) | 27/74 (36%) | 4/10 (40%) | 5/25 (20%) | .289 | .286 |
| Del(9q) | 16/109 (15%) | 10/74 (14%) | 3/10 (30%) | 3/25 (12%) | .351 | .773 |
| +8 | 6/109 (6%) | 4/74 (5%) | 0/10 (0%) | 2/25 (8%) | .801 | .999 |
| Gene mutations | ||||||
| FLT3-TKD | 4/110 (4%) | 2/74 (3%) | 1/11 (9%) | 1/25 (4%) | .380 | .596 |
| FLT3-ITD | 10/110 (9%) | 5/74 (7%) | 0/11 (0%) | 5/25 (20%) | .156 | .291 |
| KIT-Ex8 | 12/110 (11%) | 6/74 (8%) | 2/11 (18%) | 4/25 (16%) | .294 | .202 |
| KIT-Ex17 | 24/110 (22%) | 17/74 (23%) | 1/11 (9%) | 6/25 (24%) | .629 | .807 |
| KIT (total) | 35/110 (32%) | 22/74 (31%) | 3/11 (27%) | 9/25 (36%) | .902 | .830 |
| K-RAS or N-RAS | 20/110 (18%) | 13/74 (18%) | 1/11 (9%) | 6/24 (24%) | .589 | .798 |
| Any receptor tyrosine kinase mutation | 47/110 (43%) | 29/74 (39%) | 4/11 (36%) | 14/25 (56%) | .355 | .310 |
| Early response and outcome | ||||||
| Day 16 bone marrow (>5% blasts)‡ | 12/75 (16%) | 11/50 (22%) | 0/9 (0%) | 1/16 (6.25%) | .156 | .052 |
| Complete remission | 110/110 | 74/74 | 11/11 | 25/25 | NA | NA |
| Patients achieving more than 3 log-fold reduction in RUNX1-RUNX1T1 transcripts at MRD2¶ | 74/101 (73%) | 47/65 (72%) | 9/11 (82%) | 18/25 (72%) | .330 | .193 |
| 3-year cumulative incidence of relapse, % [95% confidence interval] | 30.1 [22.9-40.7] | 25.0 [16.3-37.2] | 54.6 [29.3-83.3] | 36.0 [20.6-57.8] | .226 | .103 |
| 3-year overall survival, % [95% confidence interval] | 80.1 [72.0-87.3] | 79.8 [68.1-87.5] | 81.8 [44.7-95.1] | 84.0 [62.8-93.7] | .881 | .620 |
| Patient characteristics . | All patients (n = 110) . | ASXL1/2 wild-type (n = 74) . | ASXL1 mutant (n = 11) . | ASXL2 mutant (n = 25) . | P* . | P† . |
|---|---|---|---|---|---|---|
| Age, median [range] (years) | 31 [4-60] | 33 [4-59] | 35 [7-47] | 22 [4-60] | .265 | .227 |
| Sex (M/F) | 59/51 | 43/31 | 5/6 | 11/14 | .400 | .223 |
| WBC, median [range] (G/L) | 12.8 [1.3-163] | 10.7 [1.3-94.5] | 15.8 [3.4-48.2] | 20.3 [2.7-163] | .029 | .011 |
| Blasts, [range] % | 55 [17-98] | 58 [17-98] | 45 [28-81] | 50 [25-94] | .140 | .047 |
| Additional cytogenetic abnormalities | ||||||
| Loss of Y | 36/109 (33%) | 27/74 (36%) | 4/10 (40%) | 5/25 (20%) | .289 | .286 |
| Del(9q) | 16/109 (15%) | 10/74 (14%) | 3/10 (30%) | 3/25 (12%) | .351 | .773 |
| +8 | 6/109 (6%) | 4/74 (5%) | 0/10 (0%) | 2/25 (8%) | .801 | .999 |
| Gene mutations | ||||||
| FLT3-TKD | 4/110 (4%) | 2/74 (3%) | 1/11 (9%) | 1/25 (4%) | .380 | .596 |
| FLT3-ITD | 10/110 (9%) | 5/74 (7%) | 0/11 (0%) | 5/25 (20%) | .156 | .291 |
| KIT-Ex8 | 12/110 (11%) | 6/74 (8%) | 2/11 (18%) | 4/25 (16%) | .294 | .202 |
| KIT-Ex17 | 24/110 (22%) | 17/74 (23%) | 1/11 (9%) | 6/25 (24%) | .629 | .807 |
| KIT (total) | 35/110 (32%) | 22/74 (31%) | 3/11 (27%) | 9/25 (36%) | .902 | .830 |
| K-RAS or N-RAS | 20/110 (18%) | 13/74 (18%) | 1/11 (9%) | 6/24 (24%) | .589 | .798 |
| Any receptor tyrosine kinase mutation | 47/110 (43%) | 29/74 (39%) | 4/11 (36%) | 14/25 (56%) | .355 | .310 |
| Early response and outcome | ||||||
| Day 16 bone marrow (>5% blasts)‡ | 12/75 (16%) | 11/50 (22%) | 0/9 (0%) | 1/16 (6.25%) | .156 | .052 |
| Complete remission | 110/110 | 74/74 | 11/11 | 25/25 | NA | NA |
| Patients achieving more than 3 log-fold reduction in RUNX1-RUNX1T1 transcripts at MRD2¶ | 74/101 (73%) | 47/65 (72%) | 9/11 (82%) | 18/25 (72%) | .330 | .193 |
| 3-year cumulative incidence of relapse, % [95% confidence interval] | 30.1 [22.9-40.7] | 25.0 [16.3-37.2] | 54.6 [29.3-83.3] | 36.0 [20.6-57.8] | .226 | .103 |
| 3-year overall survival, % [95% confidence interval] | 80.1 [72.0-87.3] | 79.8 [68.1-87.5] | 81.8 [44.7-95.1] | 84.0 [62.8-93.7] | .881 | .620 |